David H Coy
Overview
Explore the profile of David H Coy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
1478
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vasilevich N, Jiang H, Xiao H, Feng K, Jian C, Chen C, et al.
Biochem Biophys Res Commun
. 2024 Jan;
696:149483.
PMID: 38219484
Highly cytotoxic maytansine derivatives are widely used in targeted tumor delivery. Structure-activity studies published earlier suggested the C9 carbinol to be a key element necessary to retain the potency. However,...
2.
Lei J, Sun L, Huang S, Zhu C, Li P, He J, et al.
Am J Transl Res
. 2019 Aug;
11(7):3919-3931.
PMID: 31396309
Nowadays, the bacterial drug resistance leads to serious healthy problem worldwide due to the long-term use and the abuse of traditional antibiotics result in drug resistance of bacteria. Finding a...
3.
Starr C, Maderdrut J, He J, Coy D, Wimley W
Peptides
. 2018 Apr;
104:35-40.
PMID: 29654809
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a naturally occurring cationic peptide with potent immunosuppressant and cytoprotective activities. We now show that full length PACAP38 and to a lesser extent, the...
4.
Sun L, He Q, Tsai C, Lei J, Chen J, Vienna Makcey L, et al.
Am J Transl Res
. 2018 Mar;
10(2):545-553.
PMID: 29511449
Small cell lung cancer (SCLC) is a malignant human cancer and patients have very limited benefit from traditional anticancer treatments, with a poor five-year survival rate being 10% less. In...
5.
Subramaniam V, Chuang G, Xia H, Burn B, Bradley J, Maderdrut J, et al.
Peptides
. 2017 Jul;
95:25-32.
PMID: 28720396
Mitoxantrone (MXT) is an androstenedione that is used to treat cancers and progressive forms of multiple sclerosis; however, its use is limited by its cardiotoxicity. Pituitary adenylate cyclase activating polypeptide...
6.
Zhu B, Sun L, Luo W, Li M, Coy D, Yu L, et al.
Oncotarget
. 2017 Apr;
8(14):23289-23302.
PMID: 28423575
Hepatocellular carcinoma (HCC) is one of the most malignant cancers. Conventional therapies are limited due to the human liver being such a unique organ and easily showing side-effects. The unclear...
7.
Sun L, Liu M, Sun G, Yang X, Qian Q, Feng S, et al.
J Cancer
. 2016 Jul;
7(11):1388-95.
PMID: 27471554
Cervical cancer is a second leading cancer death in women world-wide, with most cases in less developed countries. Notch signaling is highly conserved with its involvement in many cancers. In...
8.
Leclair E, Liggins R, Peckett A, Teich T, Coy D, Vranic M, et al.
Diabetologia
. 2016 Apr;
59(8):1724-31.
PMID: 27075449
Aims/hypothesis: Regular exercise is at the cornerstone of care in type 1 diabetes. However, relative hyperinsulinaemia and a blunted glucagon response to exercise promote hypoglycaemia. Recently, a selective antagonist of...
9.
Sun L, Coy D
Curr Drug Targets
. 2016 Mar;
17(5):529-37.
PMID: 26951062
Somatostatin (SST) is a cyclic hormone-release inhibitory peptide that has high binding affinity to all of its five SST receptors (SSTRs). SST negatively regulates cell proliferation and the release of...
10.